Research programme: cancer therapeutics - Oncoceutics

Drug Profile

Research programme: cancer therapeutics - Oncoceutics

Alternative Names: Imipridone compounds - Oncoceutics; ONC 202; ONC 206; ONC 212; ONC 213; ONC 222; ONC 235; ONC 400

Latest Information Update: 15 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncoceutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Extracellular signal-regulated MAP kinase inhibitors; Proto oncogene protein c-akt inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Ewing's sarcoma

Most Recent Events

  • 19 Dec 2017 Oncoceutics has patent protection for ONC 212 in USA
  • 19 Dec 2017 Oncoceutics announces intention to submit an IND application for ONC 206 for Cancer in 2018
  • 09 Dec 2017 Pharmacodynamics data from a preclinical study in Breast cancer presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top